title: Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression.
authors.forename: Marielle J
authors.initials: MJ
authors.lastname: Wondergem
authors.forename: Servi J C
authors.initials: SJ
authors.lastname: Stevens
authors.forename: Jeroen J W M
authors.initials: JJ
authors.lastname: Janssen
authors.forename: Joost J
authors.initials: JJ
authors.lastname: Oudejans
authors.forename: Gert J
authors.initials: GJ
authors.lastname: Ossenkoppele
authors.forename: Jaap M
authors.initials: JM
authors.lastname: Middeldorp
authors.forename: Sonja
authors.initials: S
authors.lastname: Zweegman
mesh_terms: D000328:Adult; D000741:Anemia, Aplastic / Q000276:immunology* / Q000628:therapy* / Q000821:virology; D000818:Animals; D000961:Antilymphocyte Serum / Q000276:immunology* / Q000627:therapeutic use*; D005260:Female; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy; D011817:Rabbits; D014775:Virus Activation
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents